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See Articles, pages 714–720 and 728–735In recent years, major advances have been made in
our understanding of the natural history and manage-
ment of patients with chronic hepatitis B. Large cohort
studies have clearly established the link between level of
viremia and adverse outcomes, including both hepato-
cellular carcinoma (HCC) and cirrhosis [1,2]. Further-
more, a spontaneous decline in HBV DNA level has
been correlated with improved outcomes [1], suggesting
that pharmacological suppression may achieve the same
ends. Consistent with this, clinical trials have already
conﬁrmed a positive impact of antiviral therapy on dis-
ease outcomes [3–5].
In parallel with these developments has come evi-
dence that relatively low viral levels, and normal or only
slightly elevated ALT levels can be associated with sig-
niﬁcant liver disease and adverse clinical outcomes
[1,2,6–8]. Although the evidence-based treatment guide-
lines promulgated by the international liver associations
have featured deﬁned viral load cut-oﬀs and threshold
levels of ALT above normal to deﬁne treatment candi-
dacy [9–11] there has been a trend among many clini-
cians to broaden the spectrum of patients with HBV
infection in whom therapy is considered appropriate
[12].
The crystallization of the link between reduction in
viremia and improved outcomes, and the inexorable
increase in the population expected to be treated in the
future, have sharpened the focus on what might be0168-8278/$34.00  2008 European Association for the Study of the Liver.
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long-term viral suppression and avoidance of resistance.
These pillars have been fortiﬁed with the introduction
over the past decade of four approved oral antiviral
agents, along with peginterferon alfa-2a. Other oral
agents are in the late phase of development, such as ten-
ofovir [13,14], already available as an approved treat-
ment for human immunodeﬁciency virus (HIV), and
clevudine, for which there is suggestive evidence of a
capacity to induce sustained viral suppression after cessa-
tion of therapy, even in HBeAg-negative patients [15].
Yet, despite the increased level of conﬁdence, clinicians
have in their ability to treat patients eﬀectively, whether
it be those with ‘‘conventional indications” on which all
experts would agree, or with ‘‘expanded indications” that
engender ongoing controversy, major limitations remain.
These limitations can be classiﬁed as follows: (1)
HBV DNA remains detectable in some patients even
with the most potent agents, particularly those who
are HBeAg-positive; (2) Even when HBV DNA becomes
undetectable, HBeAg seroconversion does not ensue at
proportional frequency. Indeed, the pivotal trials of
entecavir, telbivudine, and tenofovir have underscored
the biologic diﬀerence underlying viral suppression and
HBeAg seroconversion. As eﬀective as these agents have
proven to be in reducing HBV DNA levels, HBeAg sero-
conversion rates have not improved substantially rela-
tive to those obtained with earlier treatments; (3) In
HBeAg-negative patients, we still lack an oral agent(s)
that allows for cessation of therapy with an acceptable
rate of durable viral suppression subsequently; (4)
Although oral agents are not wholly incapable of induc-
ing HBsAg loss, the rates are low, with 3% of HBeAg-
positive patients receiving tenofovir [14] and 5% of
HBeAg-positive patients receiving entecavir [16] achiev-Published by Elsevier B.V. All rights reserved.
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and (5) All long-term monotherapies have been shown
to be capable of selecting for resistance, although the
resistance rates with drugs having a high genetic barrier
to resistance have been reassuringly low. The resistance
rate with adefovir in HBeAg-negative patients is only
6% at up to 192 weeks if HBV DNA is under 1000 cop-
ies/ml at one year of treatment. In the aggregate, how-
ever, the incidence of genotypic resistant mutations is
29% at ﬁve years [17]. The rate of resistance to entecavir
has been reported to be less than 1% cumulatively after
four years [18]. Although a feature of the entecavir
(ETV) pivotal trials was that a subset of patients, rather
than all patients, received treatment beyond one year,
many HBeAg-positive patients (predominantly those
with ‘‘virologic only response” who failed to clear
HBeAg at 48 weeks) did receive ETV 1.0 mg daily for
as long as three additional years in a rollover study after
the initial year of ETV 0.5 mg daily. The data from this
cohort [18], including a recently reported subset of 21
HBeAg-positive patients with virological non-response
to ETV after 48 weeks [19], support the conclusion that
the drug’s resistance proﬁle after prolonged therapy is
very robust. Nevertheless, the drug is not entirely free
of a risk of resistance.
All these limitations have fuelled intense interest in
combination regimens for chronic hepatitis B. In theory,
at least, combination therapy might improve upon
monotherapy with regard to any or all of the above end-
points. Support for this concept comes from the many
lessons learned with human immunodeﬁciency virus
(HIV) therapy, as well as the emerging story of therapy
for chronic hepatitis C [20], where it is widely antici-
pated that combinations of speciﬁcally targeted antiviral
agents will be necessary to optimize responses and min-
imize problems with resistance.
Very few studies exploring this approach to HBV
therapy have been reported to date. The phase 2 trial
of telbivudine featured three arms: lamivudine alone,
telbivudine alone, and telbivudine combined with lami-
vudine [21]. The degree of viral suppression after one
year was no greater with combination therapy than with
telbivudine, though each was superior to lamivudine,
and combination therapy was actually slightly inferior
to telbivudine monotherapy in attaining clinical eﬃcacy
endpoints, including HBeAg loss or seroconversion and
viral breakthrough. Although the reasons for these
observations are not clear [21], it seems prudent to avoid
using drugs with cross-resistance, such as lamivudine
and telbivudine, in combination. This point has been
underscored by recent data demonstrating excellent sup-
pression, with virtually no long-term resistance to adefo-
vir, when that drug is added to lamivudine in patients
who have developed lamivudine resistance [22].
The present issue of the Journal features two papers
which expand our knowledge about the potentialadvantages of oral combination therapy [23,24]. The
preliminary results of the placebo-controlled study in
HBeAg-positive patients by Sung et al. of lamivudine
monotherapy (n = 57) versus lamivudine plus adefovir
(n = 54) were presented in abstract form shortly after
adefovir was approved [25] and its ﬁnal publication
at this time [23] has long been awaited. Reductions in
HBV DNA were comparable between the two treat-
ment arms at week 16 (the primary study endpoint)
and during the ﬁrst 52 weeks, but after 104 weeks med-
ian HBV DNA reductions were 3.41 log and
5.22 log, respectively. Similarly, HBV DNA was
<200 copies/ml in 41% and 40% at 52 weeks, but
14% versus 26% at 104 weeks. The diﬀerence in viro-
logic outcome was associated with a higher rate of viral
breakthrough in the monotherapy group than in the
combination group (44% vs 19%). Not all the break-
throughs were associated with genotypic resistance,
and a surprisingly small number of patients (only three
in both groups combined) had genotypic mutations
without virologic breakthrough, even though patients
had to have not only a 1 log increase in HBV DNA
from nadir but at least one value >104 copies/ml to
be classiﬁed as having had a breakthrough. In the lam-
ivudine monotherapy group, the M204V/I mutation
was detected in 20% and 43% at weeks 52 and 104,
compared with 9% and 15% at the same time points
in the combination therapy group. The N236T muta-
tion was noted in only one adefovir recipient. Notably,
the rate of HBeAg seroconversion was identical, at
35%, in each group.
The results of this trial indicate that the addition of a
nucleotide with an excellent short-term resistance proﬁle
to a nucleoside with a lower genetic barrier to resistance
eﬀectively decreases the risk of emergent resistance to
the latter drug, despite the relative limitation on viral
suppression by the former drug imposed by dosing con-
straints. However, such a combination does not provide
additive viral suppression early in therapy, the incre-
ment in viral decline in the longer term presumably
being attributable mostly or entirely to the prevention
of viral breakthrough. Moreover, the risk of lamivudine
resistance even in the combination group was far from
negligible. Thus, the ﬁrst ‘‘pillar” of HBV therapy, pro-
found viral suppression, is not strengthened signiﬁcantly
by such a combination, while the second, prevention of
resistance, is strengthened but only relatively. These
ﬁndings reinforce the need for consideration of the fea-
tures and limitations of the individual agents incorpo-
rated into studies of combination regimens. The results
of the paper by Sung et al. [23] also warrant circumspec-
tion among clinicians who may have chosen in the past
to use a combination of lamivudine and adefovir in
patients in whom resistance could have particularly
adverse implications, such as cirrhotic patients. Clearly,
the results of studies in which adefovir resistance rarely
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resistant patients [22] cannot be extrapolated to
the question of how frequently lamivudine resistance
emerges when the two drugs are co-administered to
treatment-naı¨ve patients.
Added perspective on combination regimens is pro-
vided by a second paper published in this issue of the
Journal by Hui et al. [24], comparing adefovir (n = 16)
alone to a combination of adefovir plus emtricitabine
(n = 14), a nucleoside analog with activity and a resis-
tance proﬁle similar to that of lamivudine, in HBeAg-
positive patients for 96 weeks. Despite the small number
of patients in the study, a signiﬁcant advantage for com-
bination therapy was achieved, with median HBV DNA
declines of 3.98 log10 copies/ml versus 5.30 log10
copies/ml for monotherapy and combination therapy,
respectively, at 96 weeks (p = 0.05), and HBV DNA
<300 copies/ml in 37.5% versus 78.5%. In contrast to
the study by Sung et al. [23], the diﬀerence in viral sup-
pression was noted early in treatment by Hui et al. [24],
as early as 4 weeks as suggested in Fig. 1, thereby prov-
ing to be related to diﬀerences in the intrinsic antiviral
eﬃcacy of the two regimens. All four viral break-
throughs in the study occurred at 64 weeks and beyond;
three of these occurred in the combination group but
none was associated with drug-resistant mutations, nor
were genotypic mutations noted in nine other patients
from the adefovir monotherapy group. In a recurrent
theme from the cumulative literature, there was no dif-
ference in the incidence of HBeAg seroconversion
despite the diﬀerence in viral suppression between the
two regimens.
The design of this small trial makes it diﬃcult to
assess the degree to which the greater suppression of
HBV DNA with the combination regimen was attribut-
able to a contributory eﬀect of adefovir or simply repre-
sented the eﬃcacy of the more potent drug,
emtricitabine. The limitation on interpretability posed
by the absence of an emtricitabine monotherapy arm
is fully acknowledged by the authors. In an earlier trial
of emtricitabine versus placebo [26], 39% of HBeAg-
positive patients receiving emtricitabine had undetect-
able HBV DNA at week 48 compared with 78.5% in
the recipients of emtricitabine plus adefovir in the pres-
ent study [24]. In the latter study, the limit of detection
for HBV DNA was 300 copies/ml whereas in the former
it was 400 copies/ml, perhaps underscoring a true diﬀer-
ence in viral suppression, but cross-study comparisons
are intrinsically problematic and especially so in this
case given the very small number of patients in the pres-
ent study. Moreover, the median decline of HBV DNA
at 48 weeks in the trial of emtricitabine monotherapy
was 4.7 log10 copies/ml [26], only slightly lower than
that observed with adefovir and emtricitabine in this
study [24]. Perhaps the most striking apparent beneﬁt
of combination therapy in this study is that there wasnot only a relative decline in resistance to emtricitabine,
as occurred with lamivudine resistance in the study by
Sung et al. [23], but a complete absence of resistance.
In contrast, in the emtricitabine monotherapy trial,
resistance occurred in 13% at 48 weeks [26], reminiscent
of, if not quite matching, resistance rates with lamivu-
dine. Thus, although once again the relatively small
number of patients precludes any notion of complete
protection against resistance, this study provides
another important indication that for drugs with a low
genetic barrier to resistance, the concomitant adminis-
tration of a HBV drug with a higher genetic barrier
can prevent resistance to the former.
The two studies reported in the Journal this month
[23,24] are of value in serving as prototypes for the
important work still needed in this ﬁeld, but they fall
short of establishing a deﬁnitive role for routine combi-
nation therapy in all patients when potent monothera-
pies with robust long-term resistance proﬁles are
available. For example, the 4-year data on entecavir sug-
gest cumulative rates of HBV DNA undetectability
exceeding 90% in HBeAg-positive patients after four
years and, as cited above, a reported cumulative resis-
tance rate of under 1% [18]. The recently presented piv-
otal trial data on tenofovir demonstrate potent
suppression, with 93% and 76% of HBeAg-negative
and HBeAg-positive patients having undetectable HBV
DNA, respectively, after one year, and no genotypic
resistance [13,14]. It seems likely from these and other
data [27], as well as experience in HBV/HIV co-infected
patients [28], that this drug, too, will prove to have a
robust long-term resistance proﬁle. Telbivudine, which
confers excellent viral suppression but has a less robust
resistance proﬁle than entecavir or the nucleotides, has
recently been associated with 2-year resistance rates of
2% or less in patients who meet certain criteria for base-
line viral load and/or ALT and have undetectable HBV
DNA at 24 weeks [29].
These considerations lead to challenges for those who
wish, appropriately, to conduct additional trials of com-
bination therapy for HBV infection. Even though pre-
vention of resistance is a cornerstone of this concept,
the practical design of trials with this as the primary
endpoint is problematic when monotherapies that have
high barriers to resistance and excellent proven long-
term resistance proﬁles are already available. Thus, such
studies must emphasize serological and virologic end-
points, such as greater rates of HBV DNA suppression,
HBeAg seroconversion, HBsAg clearance, accelerated
covalent closed circular DNA (cccDNA) clearance,
and perhaps the capacity to stop therapy without viro-
logic relapse, particularly in HBeAg-negative patients,
at a deﬁnable time point. It may be that drugs with other
mechanisms of action, such as immunomodulatory
agents, including restoration of speciﬁc immune
responses, small interfering RNAs (siRNAs), entry
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be required.
A notable feature of trials evaluating combinations of
peginterferon and lamivudine is a more profound
decrease in viral load than that observed with either
monotherapy. However, post-treatment endpoints such
as viral suppression, HBeAg seroconversion, and
HBsAg clearance have not been signiﬁcantly diﬀerent
from those noted with peginterferon alone, which is
superior to lamivudine alone [30,31]. These trials
entailed the discontinuation of lamivudine, like pegin-
terferon, after one year, which is not done in practice.
While the search for alternative approaches to combina-
tion therapy continues, including the potential for com-
bining peginterferon with other nucleos(t)ide analogs
entailing more prolonged administration of the oral
agent, further trials combining nucleos(t)ide analogs,
such as those currently being conducted with such com-
binations as tenofovir and emtricitabine, entecavir and
tenofovir, entecavir and adefovir, and tenofovir and tel-
bivudine [32], are abundantly worthwhile.
In the meantime, results such as those from the trials
reported in this issue of the Journal, despite their limita-
tions, provide support, along with other published data,
for the use of oral combination therapy (albeit oﬀ-label)
in selected situations such as (a) in patients with cirrho-
sis who can ill-aﬀord emergent resistance; (b) when there
has been suboptimal response to initial monotherapy at
a speciﬁed time point, such as 24 weeks of a drug with a
low genetic barrier to resistance or one year of a drug
with a high barrier [33]; (c) in patients co-infected with
HIV and HBV; and (d) in any setting in which there is
established resistance to a HBV drug. However, the uni-
versal application of combination therapy to all patients
undergoing treatment for chronic hepatitis B requires a
ﬁrmer foundation in comparative trials with potent
agents used as monotherapy before it goes from the con-
troversial to the routine.References
[1] Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of
hepatocellular carcinoma across a biological gradient of serum
hepatitis B virus DNA level. JAMA 2006;295:65–73.
[2] Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al.
Predicting cirrhosis risk based on the level of circulating hepatitis
B viral load. Gastroenterology 2006;130:678–686.
[3] Niederau C, Heintges T, Lenge S, Goldmann G, Niederau CM,
Mohr L, et al. Long-term follow-up of HbeAg-positive patients
treated with interferon alfa for chronic hepatitis B. N Engl J Med
1996;334:1422–1427.
[4] Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al.
Lamivudine for patients with chronic hepatitis B and advanced
liver disease. N Engl J Med 2004;351:1521–1531.
[5] Di Marco V, Marzano A, Lampertico P, Andreone P, Santanto-
nio T, Almasio PL, et al. Clinical outcome of HBeAg-negative
chronic hepatitis in relation to virological response to lamivudine.
Hepatology 2004;40:883–891.[6] Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical
signiﬁcance of persistently normal ALT in chronic hepatitis B
infection. J Hepatol 2007;47:760–767.
[7] Yang LM, Xu KC, Zhao YL, Wu ZR, Chen TF, Qin ZY, et al.
Clinical signiﬁcance of liver biopsy in chronic hepatitis B patients
with persistently normal transaminases. Chin J Dig Dis
2002;4:150–153.
[8] Yuen MF, Yuan HJ, Wong DKH, Yuen JC, Wong WM, Chan
AO, et al. Prognostic determinants for chronic hepatitis B in
Asians: therapeutic implications. Gut 2005;54:1610–1614.
[9] Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology
2007;45:507–539.
[10] EASL International Consensus Conference on Hepatitis B. J
Hepatol 2003;38:S3–S25.
[11] Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan
G, et al. Asian-paciﬁc consensus statement on the management
of chronic hepatitis B: a 2005 update. Liver Int 2005;25:
472–489.
[12] Keeﬀe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiﬀ
ER, et al. A treatment algorithm for the management of chronic
hepatitis B virus infection in the United States: an update. Clin
Gastroenterol Hepatol 2006;4:936–962.
[13] Marcellin P, Buti M, Krastev Z, Germanidis G, Kaita KD,
Kotzev I, et al. A randomized, double-blind, comparison of
tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the
treatment of HBeAg-negative chronic hepatitis B (CHB): Study
GS-US-174-0102. American Association for the Study of Liver
Diseases, 58th annual meeting, 2007: late breaking abstract 2.
Hepatology 2007;46:290A.
[14] Heathcote EJ, Gane E, DeMan R, Lee S, Flisiak R, Manns MP,
et al. A randomized, double-blind, comparison of tenofovir DF
(TDF) versus adefovir dipivoxil (ADV) for the treatment ofHBeAg
positive chronic hepatitis B (CHB): Study GS-US-174-0103.
American Association for the Study of Liver Diseases, 58th annual
meeting, 2007: late breaking abstract 6. Hepatology 2007;46:861A.
[15] Yoo BC, Kim JH, Kim TH, Koh KC, Um SH, Kim YS, et al.
Clevudine is highly eﬃcacious in hepatitis B e antigen-negative
chronic hepatitis B with durable oﬀ therapy viral suppression.
Hepatology 2007;46:1041–1048.
[16] Gish R, Chang TT, Lai CL, de Man R, Gadano A, Poordad F,
et al. Hepatitis B surface antigen loss in antiviral-treated patients
with HBeAg-positive chronic hepatitis B infection: observations
from antiviral-naı¨ve patients treated with entecavir or lamivudine.
57th annual meeting of the American Association for the Study of
Liver Diseases, 2006. Hepatology 2006;44:558A.
[17] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis
G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil
for HBeAg-negative chronic hepatitis B for up to 5 years.
Gastroenterology 2006;131:1743–1751.
[18] Han S, Chang TT, Chao YC, Yoon S-K, Gish RG, Cheinquer H,
et al. Four-year entecavir treatment in nucleoside-naive HbeAg+
patients: results from studies ETV-022 and -901. Hepatology
2007;46:654A.
[19] Sherman M, Rizzetto M, Lai CL, Liaw Y-F, Gadano A, Jacobson
IM, et al. Long-term follow-up of entecavir treated protocol-
deﬁned nonresponders in rollover study ETV-901. Hepatology
2007;46:682A.
[20] Kieﬀer TL, Sarrazin C, Miller JS, Welker MW, Forestier N,
Reesink HW, et al. Telaprevir and pegylated interferon-alpha-2a
inhibit wild type and resistant genotype 1 hepatitis C virus
replication in patients. Hepatology 2007;46:631–639.
[21] Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A
1-year trial of telbivudine, lamivudine, and the combination in
patients with hepatitis B e antigen-positive chronic hepatitis B.
Gastroenterology 2005;129:528–536.
[22] Lampertico P, Vigano` M, Manenti E, Iavarone M, Sablon E,
Colombo M. Low resistance to adefovir combined with lamivu-
I.M. Jacobson / Journal of Hepatology 48 (2008) 687–691 691dine: a 3-year study of 145 lamivudine-resistant hepatitis B
patients. Gastroenterology 2007;133:1445–1451.
[23] Sung JJY, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo
RP, et al. Lamivudine compared with lamivudine and adefovir
dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.
J Hepatol 2008;48:728–735.
[24] Hui CK, Zhang HY, Bowden S, Locarnini S, Luk JM, Leung K-
W, et al. 96 weeks combination of adefovir dipivoxil plus
emtricitabine versus adefovir dipivoxil monotherapy in the treat-
ment of chronic hepatitis B. J Hepatol 2008;48:714–720.
[25] Sung JJY, Lau JY, Zeuzem S, ChowWC, Heathcote E, Perrillo R,
et al. A randomised double-blind phase II study of lamivudine
(LAM) compared to lamivudine and adefovir for treatment-naive
patients with chronic hepatitis B (CHB): week 52 analysis. J
Hepatol 2003;38:25–26.
[26] Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, et al.
A double-blind placebo-controlled study of emtricitabine in
chronic hepatitis B. Arch Intern Med 2006;166:49–56.
[27] Van Bommel F, De Man RA, Erhardt A, Huppe D, Stein K,
Buggish P, et al. First multicenter evaluation of the eﬃcacy of
tenofovir in nucleos(t)ide analog experienced patients with HBV
monoinfection. Hepatology 2007;46:270A.[28] Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R,
Katlama C, et al. Anti-hepatitis B virus eﬃcacy of tenofovir
disoproxil fumarate in HIV-infected patients. Hepatology
2006;43:548–555.
[29] Zeuzem S, Buti M, Gane EJ, Liaw Y-F, Di Bisceglie AM,
Heathcote EJ, et al. Baseline parameters predict both early
virologic response and longer term outcomes for telbivudine-
treated patients with chronic hepatitis B (the GLOBE Study).
Hepatology 2007;46:681A.
[30] Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R,
et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in
combination in patients with HBeAg-negative chronic hepatitis B.
N Engl J Med 2004;351:1206–1217.
[31] Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S,
Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the
combination for HBeAg-positive chronic hepatitis B. N Engl J
Med 2005;352:2682–2695.
[32] http://clinicaltrials.gov/.
[33] Keeﬀe EB, Zeuzem S, Koﬀ RS, Dieterich DT, Esteban-Mur R,
Gane EJ, et al. Report of an international workshop: roadmap for
management of patients receiving oral therapy for chronic
hepatitis B. Clin Gastroenterol Hepatol 2007;5:890–897.
